Cancer News and Research

Latest Cancer News and Research

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company’s Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.

23 Oct 2009

Verizon Foundation awards $10,000 grant to The Wellness Community of the East Bay

The Wellness Community of the East Bay has been awarded a $10,000 grant from the Verizon Foundation, the philanthropic arm of Verizon, to fund the use of technology to identify the best community-based psychological and social support and education strategies for cancer patients and their families.

23 Oct 2009

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer.

23 Oct 2009

Vidacare to release results of validation study on its OnControl Bone Marrow System

Vidacare Corporation has completed an analysis and is releasing the results of a validation study on its OnControl™ Bone Marrow System, the first effort in decades to improve the safety, control, and comfort of bone marrow aspiration and biopsy procedures.

23 Oct 2009

Dig Pink Volleyball Breast Cancer Awareness campaign to raise $1 million in support of breast cancer research

The Side-Out Foundation and its Dig Pink- Volleyball Breast Cancer Awareness campaign will launch a first of its kind clinical trial this month to examine the effects of individualized treatment on patients with metastatic breast cancer.

23 Oct 2009

Yissum Research Development signs long-term multi-project collaboration agreement with Roche

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., the technology transfer arm of the University, today announced that it has signed a long-term multi-project research and license collaboration agreement with Roche.

23 Oct 2009

Physicians' negative attitudes toward obese patients can affect quality of care

Doctors have less respect for their obese patients than they do for patients of normal weight, a new study by Johns Hopkins researchers suggests. The findings raise questions about whether negative physician attitudes about obesity could be affecting the long-term health of their heavier patients.

23 Oct 2009

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Based on an extensive review of the highest quality scientific literature on psoriasis and the opinion of recognized psoriasis experts, the American Academy of Dermatology (Academy) has released new guidelines of care for the management and treatment of psoriasis with ultraviolet (UV) light therapy, also known as phototherapy. Recommendations for the use of the most common forms of UV light therapy, as stand-alone treatments or in conjunction with other therapies, were outlined, including patient considerations.

23 Oct 2009

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

Aeolus Pharmaceuticals, Inc. announced today that recent experiments in preclinical models conducted by the National Institutes of Health’s (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasure Development program have shown that AEOL 10150 can effectively increase regeneration of gastro-intestinal (GI) stem cells, reduce the severity and duration of diarrhea and improve survival when administered at 24 hours after doses of total-body irradiation that produce the lethal GI syndrome.

23 Oct 2009

Seminar focuses on approaches to improve small molecule discovery programs

Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, last week held the latest seminar in its "Innovation for Experimentation" series.

23 Oct 2009

Japanese Ministry approves marketing of AMS800 Artificial Urinary Sphincter in Japan

American Medical Systems®, a leading provider of world-class devices and therapies for both male and female pelvic health, today announced that it has received clearance from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market and distribute its AMS 800 Artificial Urinary Sphincter (AUS) in Japan, effective September 7, 2009.

23 Oct 2009

Aethlon Medical establishes ESI as a wholly owned subsidiary

Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that it has established Exosome Sciences, Inc. (ESI) as a wholly owned subsidiary of the Company.

23 Oct 2009

Report: Quality of care for insured Americans slipped in 2008

CNNMoney reports that for the first time in more than 10 years, the "overall quality of health care" for Americans insured through commercial and public plans appears to have slipped.

23 Oct 2009

AJC urges Egyptian government to allow Israeli breast cancer researchers to enter the country

The American Jewish Committee urged the Egyptian government to allow a team of Israeli breast cancer researchers to enter the country for a major conference sponsored by Susan G. Komen for the Cure, a leading breast cancer awareness group based in the U.S. The Israeli team was denied entry into Egypt earlier this week, despite having previously received the necessary clearances to attend the conference in Alexandria.

23 Oct 2009

Early diagnostic for ovarian cancer to be developed

BioProspecting NB Inc. (BPNBI) and the Atlantic Cancer Research Institute (ACRI) have established a formal collaboration to develop an early diagnostic for ovarian cancer based on BPNBI's unique, proprietary cancer management platform.

23 Oct 2009

Roche's xCELLigence RTCA SP Instrument used for in vitro testing of cells

The C-terminal domain (CTD) of RNA Polymerase II consists of multiple repeats of an evolutionary conserved motif of seven amino acids, forming a repetitive structure of 52 repeats in humans and 26 repeats in yeast. Twenty years after the first description of the RNA polymerase II C-terminal domain, its function is still unclear.

23 Oct 2009

NCI awards $2.8 million grant to Allegro Diagnostics

Allegro Diagnostics, a leader in the field of molecular diagnostics for lung cancer, has announced that its clinical study for BronchoGen(TM), a diagnostic test for patients suspected of having lung cancer, will receive up to $2.8 million in funding for a Phase I/II Fast Track Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI).

22 Oct 2009

Phase Forward releases IRT 5.0 Interactive Response Technology solution

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced a major new release of its Interactive Response Technology (IRT) solution, Phase Forward™ IRT 5.0.

22 Oct 2009

Accredo Health Group announces a 10-year renewal of its headquarters with Memphis

Accredo Health Group Inc. announced a 10-year renewal of its 240,000-square-foot headquarters at Century Center, positioning the nation's largest specialty pharmacy and a major fixture of Memphis' health care industry for future growth. The General Investment & Development Companies and Accredo agreed to renew all leases for Accredo's five-building campus, effective January 1, 2010.

22 Oct 2009

KemPharm commences KP106 Phase 1 clinical trial for ADHD

KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm’s proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.

22 Oct 2009

Cancer News and Research

Latest Cancer News and Research

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Verizon Foundation awards $10,000 grant to The Wellness Community of the East Bay

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Vidacare to release results of validation study on its OnControl Bone Marrow System

Dig Pink Volleyball Breast Cancer Awareness campaign to raise $1 million in support of breast cancer research

Yissum Research Development signs long-term multi-project collaboration agreement with Roche

Physicians' negative attitudes toward obese patients can affect quality of care

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

Seminar focuses on approaches to improve small molecule discovery programs

Japanese Ministry approves marketing of AMS800 Artificial Urinary Sphincter in Japan

Aethlon Medical establishes ESI as a wholly owned subsidiary

Report: Quality of care for insured Americans slipped in 2008

AJC urges Egyptian government to allow Israeli breast cancer researchers to enter the country

Early diagnostic for ovarian cancer to be developed

Roche's xCELLigence RTCA SP Instrument used for in vitro testing of cells

NCI awards $2.8 million grant to Allegro Diagnostics

Phase Forward releases IRT 5.0 Interactive Response Technology solution

Accredo Health Group announces a 10-year renewal of its headquarters with Memphis

KemPharm commences KP106 Phase 1 clinical trial for ADHD

Understanding the DNA Damage Response in Innate Immunity eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in